trending Market Intelligence /marketintelligence/en/news-insights/trending/wcf81mtx0oev2ixsghmncq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Evelo Biosciences, US developer of microbials to treat cancer, closes $85M IPO

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Evelo Biosciences, US developer of microbials to treat cancer, closes $85M IPO

Evelo Biosciences Inc. closed its IPO of 5,312,500 common shares at $16 apiece to raise $85 million in gross proceeds.

The Cambridge, Mass.-based company has granted the underwriters an overallotment option to buy up to an additional 796,875 shares.

Evelo's common stock began trading on the Nasdaq Global Select Market on May 9 under the ticker symbol EVLO.

Morgan Stanley, Cowen and BMO Capital Markets acted as book-running managers for the offering. JMP Securities acted as lead manager for the offering.

Evelo develops monoclonal microbials to treat inflammatory diseases and cancer by acting on the gut-body network.